Medarex and Lonza Sign Collaboration Agreement for the Supply of Antibody-Based Products
09 Julho 2009 - 2:30AM
Business Wire
Lonza and Medarex, Inc. (NASDAQ:MEDX) today announced that they
have signed an agreement giving Medarex the option to work with
Lonza as a collaboration partner to provide manufacturing services
in support of the development and commercialization of Medarex�s
pipeline of therapeutic proteins and antibody drug conjugates
(ADCs). As part of the agreement, Lonza may provide process
development services for certain Medarex programs and may reserve
manufacturing capacity for Medarex antibody and antibody drug
conjugate programs at Lonza�s biopharmaceutical facilities around
the world. Further details of the agreement were not disclosed.
�We are pleased to be working with such a successful mid-size
biotech company to advance and strengthen their robust portfolio of
innovative therapies,� said Dr. Stephan Kutzer, Head of Lonza
Biopharmaceuticals. �Supporting Medarex�s immediate and long-term
needs with our expertise in mammalian cell culture and antibody
drug conjugates is both exciting and rewarding.�
This collaboration agreement represents the continued extension
of Lonza�s contract manufacturing business model, evolving from a
short-term product-by-product development and manufacturing
arrangement toward more strategic long-term collaboration on a
pipeline of products. The Medarex agreement leverages Lonza�s
expertise and asset base in biologics manufacturing and its new
state-of-the-art facilities to produce antibody drug conjugates in
milligram to multiple kilogram quantities for both clinical and
commercial supply.
Medarex�s biologics portfolio is focused on treating oncology
and immunology therapeutic indications with ten antibody programs
in Phase 3 to Phase 1 clinical development. Medarex is a leader in
therapeutic antibody development, and there are over forty
therapeutic product candidates derived from its UltiMAb� technology
in development or at the IND submission stage for clinical trials,
either through its internal efforts or through partnerships. Under
the terms of the agreement, Lonza may be supporting a portion of
the Medarex product pipeline.
About Lonza
Lonza is one of the world's leading suppliers to the
pharmaceutical, healthcare and life science industries. Its
products and services span its customers� needs from research to
final product manufacture. Lonza is the global leader in the
production and support of active pharmaceutical ingredients both
chemically as well as biotechnologically. Biopharmaceuticals are
one of the key growth drivers of the pharmaceutical and
biotechnology industries. Lonza has strong capabilities in large
and small molecules, peptides, amino acids and niche bioproducts
which play an important role in the development of novel medicines
and healthcare products. Lonza is a leader in cell-based research,
endotoxin detection and cell therapy manufacturing. Lonza is also a
leading provider of value chemical and biotech ingredients to the
nutrition, hygiene, preservation, agro and personal care
markets.
Lonza is headquartered in Basel, Switzerland and is listed on
the SWX Swiss Exchange. In 2008, Lonza had sales of CHF 2.937
billion. Further information can be found at www.lonza.com.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery,
development and potential commercialization of fully human
antibody-based therapeutics to treat life-threatening and
debilitating diseases, including cancer, inflammation, autoimmune
disorders and infectious diseases. Medarex applies its UltiMAb�
technology and product development and clinical manufacturing
experience to generate, support and potentially commercialize a
broad range of fully human antibody product candidates for itself
and its partners. Over forty of these therapeutic product
candidates derived from Medarex technology are in human clinical
testing or have had INDs submitted for such trials, with the most
advanced product candidates currently approved for commercial sale,
the subject of regulatory applications for marketing authorization
or in Phase 3 clinical trials. Medarex is committed to building
value by developing a diverse pipeline of antibody products to
address the world�s unmet healthcare needs. For more information
about Medarex, visit its website at www.medarex.com.
Medarex Statement on Cautionary Factors
Except for the historical information presented herein, matters
discussed herein may constitute forward-looking statements, as
defined in the Private Securities Litigation Reform Act of 1995,
that are subject to certain risks and uncertainties that could
cause actual results to differ materially from any future results,
performance or achievements expressed or implied by such
statements. Statements that are not historical facts, such as
statements preceded by, followed by or including the words
"expect"; "may"; "projected"; "estimated"; "suggest"; or
"potential"; or similar statements are forward-looking statements.
Medarex disclaims, however, any intent or obligation to update
these forward-looking statements. Risks and uncertainties include
risks associated with Lonza�s development services and reserve
manufacturing capacity, uncertainties related to the outcome of
clinical trials, as well as risks detailed from time to time in
Medarex's public disclosure filings with the U.S. Securities and
Exchange Commission, including its Annual Report on Form 10-K for
the fiscal year ended December 31, 2008 and its quarterly reports
on Form 10-Q. Copies of Medarex's public disclosure filings are
available from its investor relations department.
Medarex�, the Medarex logo and UltiMAb� are registered
trademarks of Medarex, Inc. All rights are reserved.
Horizon Kinetics Medical... (NASDAQ:MEDX)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Horizon Kinetics Medical... (NASDAQ:MEDX)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024